National Institutes of Health (NIH) COVID-19 Treatment Guidelines strongly recommend that REGEN-COV™ (casirivimab with imdevimab) be used in non-hospitalised COVID-19 patients at high risk of clinical progression in US

The recommendation on use of this cocktail of two monoclonal antibodies, designed specifically to block infectivity of SARS-CoV-2, is based in part on clinical data involving more than 4500 outpatients showing significant reduction in risk of hospitalization or death vs. placebo.

Source:

Biospace Inc.